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Type 1 diabetes (T1D) is the result of an autoimmune destruction
of pancreatic  cells. The cellular and molecular defects that cause
the disease remain unknown. Pluripotent cells generated from
patients with T1D would be useful for disease modeling. We show
here that induced pluripotent stem (iPS) cells can be generated
from patients with T1D by reprogramming their adult ﬁbroblasts
with three transcription factors (OCT4, SOX2, KLF4). T1D-speciﬁc
iPS cells, termed DiPS cells, have the hallmarks of pluripotency and
can be differentiated into insulin-producing cells. These results are
a step toward using DiPS cells in T1D disease modeling, as well as
for cell replacement therapy.
 cell  disease model  autoimmune  directed differentiation  endoderm
T
he study of human disease is often hindered by the lack of a
good model system. The initiation of the primary disease
process often occurs long before the patient shows any sign of
disease. Also, relevant patient tissue can be limited and difficult
to obtain. Although rodent models can give valuable insights,
these rarely fully recapitulate the human disease. Although the
nonobese diabetic (NOD) mouse has been enormously useful,
there are justifiable concerns regarding its validity as a model for
human type 1 diabetes (T1D) (1–3). Recently, human induced
pluripotent stem (iPS) cells with disease genotypes have been
generated as a tool for human disease modeling (4–7). Disease-
relevant cell types can be generated via in vitro differentiation
protocols,andinthebestcases,theseprotocolsenableaninvitro
analysis of the disease pathology. Although ES cells are the gold
standard for pluripotent stem (PS) cells, ES cells only model
diseases that can be diagnosed or predicted by simple Mendelian
genetics [e.g., cystic fibrosis (8) and Fanconi Anemia (9)]. Our
focus lies in understanding T1D, a disease with complex under-
lying genetics and unidentified environmental triggers. For T1D,
as well as other multigenic diseases, iPS cells are the best starting
point, because they are derived from patient cells and, thereby,
capture the disease genotype in a stem cell. To this date, it is not
clear whether different forms of type 1 diabetes exist, and how
genetics and environment factor influence each other in disease
onset and progression.
T1D results from the destruction of insulin-producing  cells
by the body’s own immune system. A cure could be achieved by
combining  cell replacement therapy with induction of toler-
ance to such cells. Cell replacement therapy for T1D requires a
source of glucose-responsive, insulin-secreting cells. Promising
results have been obtained by transplantation of pancreatic islets
of Langerhans or pancreatic tissue, but this approach is circum-
scribed by the limited and irregular supply of cadaveric donor
tissue, as well as the risks of treatment with immunosuppressant
drugs (10, 11). An alternative source of insulin-producing cells
are PS cells that can be differentiated into pancreatic  cells. For
example, ES cells have been differentiated in monolayer culture
along the endodermal lineage toward insulin-producing cells
(12, 13). However,  cells derived from immunologically un-
matched ES cells will likely be the targets of both allograft
reactions and the autoimmune response that caused the initial 
cell destruction.
MouseandhumanfibroblastscanbeusedtogenerateiPScells
(14–16). Recently, iPS cells have been generated from fibro-
blastsobtainedfrompatientswithvariousdiseases(4–7),butnot
for T1D. T1D-specific iPS (DiPS) cells derived from patients
offer several significant advantages. First, DiPS cells would
unquestionably contain the genotype responsible for the human
disease. Second, DiPS cells would provide an immunologically
matched autologous cell population, although dependent on
improvements in differentiation protocols. Third, and the
present focus of our work, patient-specific cells make possible
patient-specific disease modeling wherein the initiation and
progression of this poorly understood disease can be studied.
Because DiPS cells can be manipulated and studied in vitro, one
should be able to assess how the different cell types, including
differentiated  cells, and immunocytes interact to produce a
pathological phenotype. The purpose of the present study was to
derive DiPS cells from patients with T1D, and to test whether
these cells can be differentiated into the major target cell type,
the pancreatic  cell. Extending this approach to all cell types
involved in T1D could lead to an understanding of the root
causes of the disease and to the development of effective
prophylactic and therapeutic strategies.
Results
Generation of iPS Cells from Patients with T1D. Skin biopsies were
obtained from two Caucasian males with T1D of 11- and
27-years duration, respectively. Patient 1 was presented at age 21
with polyuria, polydypsia, and a blood glucose concentration of
680 mg/dL. Patient 2 was presented at age 3 in diabetic ketoac-
idosis requiring hospitalization. For both individuals, the body
mass index did not exceed 22 or 23, respectively. HLA haplo-
types, and other clinical data, are given in Table 1. Fibroblasts
obtained from skin biopsies were cultured and infected with a
combination of retroviruses encoding the transcription factors
OCT4, SOX2, and KLF4 (15). Starting 4 weeks after infections,
colonies were picked based on their morphological resemblance
tohumanEScellcoloniesandexpanded.Totestwhetherthecell
linesexpressedpluripotencymarkers,weverifiedthepresenceof
alkaline phosphatase (AP) activity, as well as staining for
antibodies to OCT4, NANOG, SOX2, TRA1-60, TRA1-81, and
SSEA4. The reprogrammed cells were positive for AP activity,
and were reactive to antibodies against all pluripotency markers
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printing verified that the T1D patient-specific DiPS lines were
generated from the parental fibroblast line and maintained a
normal karyotype (Fig. S1 and Table S1).
The analysis of pluripotency markers was extended to include
expression of the endogenous genes encoding NANOG, OCT4,
TERT, REX1, SOX2, and GDF3 by semiquantitative PCR
analysis. Expression of these genes in the DiPS lines was similar
tohumanEScells,butwasabsentintheparentalfibroblasts(Fig.
2A). As previously described, KLF4 is expressed in fibroblasts,
as well as in human ES cells and DiPS cells (Fig. 2A) (15).
Expression of -ACTIN was used as a control for RNA recovery
and to allow semiquantitative comparison of expression levels.
Omission of the reverse transcription reaction was used as a
control for specificity and gave no bands of expected size in the
semiquantitativePCRs(Fig.2A).Amoreglobalviewofthegene
expression profiles for the parental fibroblasts, DiPS, and hES
lines, was obtained using DNA microarrays. Hierarchical clus-
tering revealed that DiPS cell lines from both patients were
highly similar to the human ES cell lines HUES4, HUES6, and
HUES8 (17), while exhibiting low similarity to fibroblasts (Fig.
2B). The coefficient of determination (r2  square of the
correlation coefficient) was 0.72–0.74 for DiPS compared with
parental fibroblasts, and 0.94–0.98 for DiPS compared with
HUES cells (Table S2). We conclude that DiPS cells closely
resemble human ES cells in global gene expression as we have
described for iPS from primary human cells before (18).
To determine whether the viral transgenes were silenced, we
performed exogenous gene-specific quantitative PCR analysis.
Compared with the infected fibroblast control, the transgene
expression in the DiPS cells was low or at background levels (Fig.
2C), presumably due to anticipated viral gene silencing (15). We
conclude that the DiPS lines closely resemble human ES cells in
their expression profiles and, like other reported iPS cells, have
silenced the transgenes.
DiPS Cells Spontaneously Differentiate into Cell Types of Different
Germ Layers. DiPS cells were allowed to spontaneously differen-
tiate in embryoid body (EB) cultures. EB formation was
achieved by culturing DiPS cells in differentiation media on
low-attachment plates, followed by plating onto gelatin-coated
dishes for additional culture. We analyzed the morphologically
differentiatedcellsforexpressionofmarkersfortheendodermal
(SOX17 and FOXA2), mesodermal (SMA), and ectodermal
(TUJ1) lineages in differentiated cultures (Fig. 3A). The differ-
entiated DiPS cells were found positive for cells of all three germ
layers. Also, we verified pluripotency of DiPS cells in teratoma
formation assays. After injection of DiPS cells into immuno-
compromised mice, DiPS cells formed teratomas containing
derivatives of endoderm (glandular structures), mesoderm (car-
tilage), and ectoderm (nerve fibers, pigmented epithelium, and
melanocytes) (Fig. 3B). We conclude that patient-specific DiPS
cells can spontaneously differentiate into derivatives of all three
germ layers.
DiPS Cells Can Be Differentiated Along the Endodermal/Pancreatic
Lineage. We applied a directed differentiation protocol to the
DiPS cells to determine whether they can be differentiated
toward an insulin producing/glucose responsive cell. The proto-
col followed a stepwise differentiation protocol that relies on the
Table 1. Patient information
Patient Race Age/sex
Diagnosed
at age of
Family
history
History of
ketoacidosis
Body
mass
index Medication
Hemoglobin
A1C, % HLA
H1 Caucasian 32/male 21 First cousin with T1D Yes 22 Insulin 45 U/day sub. cut. 6.6 DR1/4
H2 Caucasian 30/male 3 None Yes 23 Insulin 60 U/day sub. cut. 7.2 DR1/13
Fig. 1. Generation of DiPS cells from T1D patients. DiPS lines were established from two T1D affected patient ﬁbroblasts lines H1 (A) and H2 (B). Displayed are
DiPSlines(A)H1.5and(B)H2.4.DetectionofAPactivityandimmunoﬂuorescenceanalysesforpresenceofpluripotencymarkersOCT4,SSEA4,NANOG,TRA1-60,
SOX2, and TRA1-81 are indicated. For immunoﬂuorescence stains corresponding nuclear stains (DAPI) visualize all cells including mouse embryonic ﬁbroblast
feeder cells.
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populations present in the developing embryo. DiPS cells were
subjected to a protocol that directs differentiation to definitive
endoderm followed by gut tube endoderm before further dif-
ferentiation into pancreatic progenitors, and finally, the -like
cell (Fig. 4A). As determined by immunofluorescence analysis
for SOX17 and FOXA2 expression, DiPS lines from both
patients could respond to WNT3A and Activin A treatment to
differentiate into definitive endoderm, similar to human ES cells
(Fig. 4B Upper). Further differentiation toward gut tube
endoderm (HNF4a and HNF1b positive), and pancreatic pro-
genitors (PDX1 and HNF6 positive) was achieved by supplying
FGF10 and cyclopamine, and FGF10, cyclopamine, retinoic
acid, and ()-Indolactam V, respectively. FOXA2 expression
was detected in both definitive endoderm and pancreatic pro-
genitors (Fig. 4B) as expected from normal embryonic devel-
opment (19). The expression of these transcription factors was
validated by semiquantitative PCR (Fig. 4C).
Further differentiation of DiPS-derived pancreatic progeni-
tors toward the endocrine lineage yielded cells that were positive
forsomatostatin,glucagon,andinsulin(Fig.5A).Insulin-positive
cells were C-peptide positive, excluding insulin uptake from the
media. Semiquantitative PCR analysis confirmed the expression
of endocrine-specific gene products of INSULIN, PDX1,
NKX2.2, GLUCAGON, and SOMATOSTATIN (Fig. 5B). To
address whether the insulin could be released on glucose stim-
ulation in vitro, we exposed the DiPS-derived insulin producing
cells to low or high concentrations of glucose. The DiPS-derived
population released human C-peptide on glucose stimulation
(Fig. 5C). The amount of released C-peptide after high (20 mM)
glucose stimulation was at least 5-fold higher than after low (2.5
mM) glucose stimulation. We conclude that DiPS cells can be
differentiated to insulin producing/glucose-responsive cells.
Discussion
Insight into the pathogenesis of T1D comes largely from rodent
models such as the NOD mouse or the BB rat. However, the
existing rodent models are not fully representative of the relevant
processesinpatientswithT1D.Indeed,insightsfromrodentmodels
have frequently not translated well to the clinic (1–3). Access to
genetically-predisposed human cells whose biological status ulti-
mately defines the disease enables previously impossible mecha-
nistic studies in vitro, and in vivo transplant systems. We have
generated human PS cells from two patients with T1D. These DiPS
cells provide a starting material for patient-specific disease mod-
eling and for testing differentiation protocols. In mice, inclusion of
c-Myc as a fourth reprogramming factor is associated with lethal
tumor formation in contrast to reprogramming with three factors
(Oct4, Sox2, and Klf4) (20). The reprogramming process described
herewasachievedbyusingthreefactors(OCT4,SOX2,andKLF4),
omitting the oncogene C-MYC. Consistent with previously de-
scribed iPS cell lines, transgene silencing was observed in DiPS cells
(4, 15, 21, 22). Induced PS cells can be generated from mouse cells
without permanent or transient integration of the transforming
factors in the genome (23, 24), and this approach has recently
extended to human cells (25). Currently, generation of human iPS
cells involves delivery of DNA in a manner that allows potential
integration into the genome, but alternative approaches are likely
to be available in the near future (26). In any event, insufficient
characterization of the reprogramming process and its product
precludes use of iPS cells in cell replacement therapy at this point.
However, the generation of patient-specific PS cells paired with
differentiation into cell types relevant to the disease promises to
provide valuable insights into disease pathogenesis. The DiPS cells
described here are pluripotent based on similarities in gene expres-
sion to human ES cells and their ability to spontaneously differ-
entiate into cells of different germ layers. Notably, we have differ-
entiated these patient-specific DiPS cell lines to a cell population
relevant to T1D, an insulin-producing and glucose-responsive
-like cell. Previously, iPS cells generated from foreskin fibroblasts,
but not from diabetes patients, using four factor reprogramming
(OCT4, SOX2, KLF4, and C-MYC) were shown to differentiate to
insulin-producing clusters (27), leaving open the task of generating
patient-specific DiPS, and testing their potential to differentiate
toward insulin-producing -like cells. Although DiPS cells can be
differentiated to insulin producing cells, the efficiency of this
process is low, possibly because the differentiation protocol has not
been optimized or due to variation in the differentiation propen-
sities of human PS cells (28). Interestingly, we observed differences
between DiPS lines from the same patient, potentially due to
transgene reactivation or incomplete silencing. As a consequence,
characterization of multiple lines and future efforts to generate
DiPS cells without viral integration will help address this issue.
As observed with human ES cells, -like cells derived from
DiPS are glucose responsive, but until the differentiation pro-
tocols are improved, it is not yet possible to directly compare
these cells with purified pancreatic  cells. In addition to
Fig. 2. Expression analysis of patient speciﬁc DiPS cells. (A) Semiquantitative
analysisofexpressionofOCT4,SOX2,REX1,NANOG,KLF4,GDF3,andACTIN.
Control PCR (no RT) is included. (B) Hierarchical cluster analysis of different
DiPS,HUESandﬁbroblastlines.(C)Quantitativeassessmentofviraltransgene
expression (tgOCT4, tgSOX2, and tgKLF4) levels. Viral transgene expression
was normalized to control infected BJ ﬁbroblasts (isolation occurred 7 days
post infection). Uninfected HUES and ﬁbroblast lines were used as controls.
The experiment was performed in duplicates and the error bars represent SD.
15770  www.pnas.orgcgidoi10.1073pnas.0906894106 Maehr et al.variation in differentiation propensities, potential deviations in
T1D disease onset and progression will require the generation of
multiple DiPS lines to reflect the human population afflicted
with T1D. The two cell lines from different patients described
here represent a starting point for this larger task.
Differentiation of DiPS cells to -like cells is relevant not only
for the long term possibility of autologous cell replacement
therapy,butalsofordiseasemodeling.Weproposetoextendthis
investigation to generate cell types of the immune system that
may allow the generation of a cellular interaction model of T1D.
This approach should provide a way to investigate T1D disease
onset and progression in vitro and/or in reconstituted animal
models. These in vitro and in vivo systems will also be useful for
testing of preventative and therapeutic strategies.
Materials and Methods
CellCulture.SkinﬁbroblastsfromT1Dpatientsandcontrolswerederivedfrom
explants of 3-mm dermal biopsies after informed consent under protocols
approved both by Harvard University and Columbia University College of
PhysiciansandSurgeons.Brieﬂy,3-mmskinbiopsiesweremincedwithscalpels
into smaller pieces, and tissue fragments were placed into a 60-mm tissue
culture dish under a sterile coverslip held down by sterilized silicon grease
underonecorner.Mediawasaddedtocompletelyimmersethecoverslip,and
disheswereincubatedat37 °Cinahumidiﬁedincubator(5%CO2).Mediawas
changedevery5dayswithoutdisturbingthecoverslip.Fibroblastsgrewoutof
the tissue fragments, and when sufﬁciently numerous, cells were trypsinized
and expanded. Subsequently, ﬁbroblasts were maintained in ﬁbroblast me-
dium (DMEM supplemented with 10% FBS, glutamine, sodium pyruvate,
nonessential amino acids, and penicillin/streptomycin). The resulting ﬁbro-
blasts lines are referred to as ﬁbroblast Harvard (H) lines 1 and 2.
Human ES cell and DiPS lines were cultured in human ES media (knockout
DMEM supplemented with 10% knockout serum replacement, 10% human
plasma fraction, 10 ng/mL bFGF, nonessential amino acids, -mercaptoetha-
nol, L-glutamine, and penicillin/streptomycin). Cultures were maintained on
mouse embryonic ﬁbroblast feeders and passaged enzymatically using either
0.05% Trypsin (GIBCO) or Collagenase type IV.
Fig.3. SpontaneousdifferentiationofDiPScellsintocellsofdifferentgermlayerorigin.(A)InvitrodifferentiationofDiPSlinesH1.5,H2.1,andH2.4inEBassays
wasfollowedbymonolayercultureandimmunostainingformarkersofectoderm(TUJ1),mesoderm(SMA),andendoderm(FOXA2andSOX17).Anoverlaywith
a nuclear stain (DAPI) is displayed. (B) Teratoma formation occurred after injection of DiPS into immunocompromised mice. Hematoxylin and Eosin staining of
teratoma sections shows nerve ﬁbers (N), melanocytes (M), pigmented epithelium (P), cartilage (C), and glandular structures (G).
Fig. 4. Stepwise differentiation of ES/DiPS cells toward -like cells. (A) Schematic representation of stepwise differentiation of human PS cells to -like cells.
DiPS cell lines H1.5, H2.1, and H2.4 differentiation to deﬁnitive endoderm (DE), gut tube endoderm (GTE) and pancreatic progenitors (PPs) indicated by (B)
immunostaining and (C) RT-PCR. SOX, SRY (sex determining region Y)-box; FOXA2, forkhead box protein A2; HNF, hepatocyte nuclear factor; PDX1, pancreatic
and duodenal homeobox 1; HB9, homeobox gene HLXB9; NKX6.1, NK6 transcription factor related, locus 1.
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dard procedures. One day before infection, 10E5 ﬁbroblasts were seeded per
well of a six well plate. Fibroblasts were infected on days 1 and 2 with a
combinationofOCT4,SOX2,andKLF4containingMoloneyviruses(constructs
were obtained from Addgene) (15). The media was changed on day 3 to
DMEM supplemented with 10% FBS, L-glutamine, penicillin/streptomycin,
nonessentialaminoacids,andsodiumpyruvate.Adaylaterthecellsweresplit
onto gelatinized 10-cm cell culture dishes. Subsequently, the cells were fed
everyotherdaywithhumanEScellmedia.GenerationofDiPSlinesH2.4,H2.3,
and H2.1b occurred with supplementation of the media with 1 mM valproic
acidduringthereprogrammingprocessasdescribedbefore(18),whereasDiPS
lines H2.1, H1.1, H1.5 were generated without addition of the chemical.
Colonies were picked starting 4 weeks after infection.
Spontaneous Differentiation. Spontaneous differentiation through EB forma-
tion was initiated by dissociation of human DiPS cells using collagenase IV
treatment,andsubsequenttransfertolowattachment6-wellplatesinknock-
out DMEM supplemented with 20% knockout serum replacement, nonessen-
tialaminoacid,-mercaptoethanol,L-glutamine,andpenicillin/streptomycin.
After 8–10 days suspension culture, EBs were transferred to gelatin-coated
plates and cultured for an additional 8–10 days as attachment culture.
For teratoma formation assays DiPS cells were collected by collagenase IV
treatment, and injected s.c. into immunocompromised mice (NOD-SCID or
SCID-Beige mice). Teratomas were collected 7–10 weeks after injection, and
processed according to standard procedures for parafﬁn embedding and
hematoxylin and eosin staining.
Directed Differentiation. Directed differentiation was conducted as described
(13, 29) with the following modiﬁcations: human DiPS cells were cultured on
MEF feeder cells to 70–80% conﬂuency, then treated with 25 ng/mL WNT3A
(R&Dsystems)100ng/mLActivinA(R&Dsystems)inadvancedRPMI(A-RPMI;
Invitrogen) supplemented with 1L-Glu and 1PS for 1 day, followed by
treatment with 100 ng/mL Activin A in A-RPMI supplemented with 1L-Glu,
1PSand0.2%FBS(Invitrogen).Twodayslater,themediawaschangedto50
ng/mL FGF10 (R&D systems)  0.25 M KAAD-CYC (Calbiochem) in A-RPMI
supplementedwith1L-Glu,1PSand2%FBSandmaintainedforadditional
2 days. Cells were then transferred to 50 ng/mL FGF10 0.25 M KAAD-CYC 2
M RA (Sigma) in DMEM supplemented with 1L-Glu, 1PS, 1 B27 (Invitro-
gen)andculturedforanadditional4days.Themediawasthenchangedto50
ng/mL FGF10  300 nM ILV (Axxora) in DMEM supplemented with 1L-Glu,
1PS, 1 B27 and cultured for an additional 4 days. Then, cells were trans-
ferred to 50 ng/mL EX-4 (Sigma)  10 M DAPT (Sigma) in DMEM supple-
mented with 1L-Glu, 1PS, 1 B27 and cultured for an additional 6 days.
Cellswerethenculturedin50ng/mLHGF(R&Dsystems)50ng/mLIGF1(R&D
systems) in CMRL-1066 (Invitrogen) supplemented with 1L-Glu, 1PS, 1
B27 for 6 days.
Immunofluorescence. Immunoﬂuorescence staining was performed using
primary antibodies against C-peptide (4020-01; Linco), FOXA2 (07-633;
Upstate), glucacon (4031; Linco), HNF6 (sc-13050; Santa Cruz Biotechnol-
ogy), insulin (A0564; Dako), NANOG (ab21624; Abcam), NKX2.5 (sc-14033;
Santa Cruz Biotechnology), OCT4 (sc-5279; Santa Cruz Biotechnology),
PDX1 (AF2419; R&D systems), SMA (A5228; Sigma), somatostatin (A0566;
Dako), SOX2 (sc-17320; Santa Cruz Biotechnology), SOX17 (AF1924; R&D
systems), SSEA4 (MAB4304; Chemicon), TRA-1–60 (MAB4360; Chemicon),
TRA-1–81 (MAB4381; Chemicon), and TUJ-1 (MMS-435P; Covance Research
Products). Appropriate secondary antibodies were obtained from Molec-
ular Probes.
Gene Expression Analysis. RNA was isolated from cells using RNAeasy kit
(Qiagen). For quantitative and semiquantitative PCR analysis, cDNA synthesis
was performed using SuperScript III Reverse Transcriptase and Oligo (dT)
primers (Invitrogen). Primers used for ampliﬁcation are listed in Table S3.
Forwhole-genomeexpressionanalysis,IlluminaTotalPrepRNAampliﬁcation
Kit (Ambion) was used according to manufacturer’s guideline. Hybridization to
Whole-GenomeExpressionBeadChips(HumanRef-8)wasfollowedbyanalysison
an Illumina Beadstation 500. All samples were prepared in duplicates. Data
analysis was conducted using manufacturer’s Beadstudio software.
C-Peptide Release Assay. C-peptide release was measured by incubating the
cells in Krebs–Ringer solution containing bicarbonate and Hepes (KRBH; 129
Fig. 5. DiPS cell lines H1.5, H2.1, and H2.4 differentiate to hormone-expressing endocrine cells indicated by (A) immunostaining and (B) semiquantitative PCR.
(C) The DiPS-derived C-peptide-expressing cells secreted C-peptide on glucose stimulation. The DiPS-derived populations were stimulated with 2.5 and 20 mM
D-glucose, and the amount of human C-peptide released to culture supernatant was analyzed by ELISA. C-PEP, C-peptide; INS, insulin; GLU, glucagon; SS,
somatostatin.
15772  www.pnas.orgcgidoi10.1073pnas.0906894106 Maehr et al.mM NaCl/4.8 mM KCl/2.5 mM CaCl2/1.2 mM KH2PO4/1.2 mM MgSO4/5 mM
NaHCO3/10mMHepes/0.1%BSA).ThecellswereincubatedinKRBHbufferfor
1 h to wash. The cells were incubated in KRBH buffer with 2.5 mM D-glucose
for 1 h and then KRBH buffer with 20 mM D-glucose for 1 h. The C-peptide
levels in culture supernatants were measured using the human C-peptide
ELISA kit (Alpco Diagnostics).
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